Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Eupraxia Pharmaceuticals Inc. Completes Initial Public Offer

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Mar 09, 2021 12:35pm

153 Views

Post# 32753315

RE:RE:Eupraxia Pharmaceuticals Inc. Completes Initial Public Offer

yes, an injection...

Corticosteroids are one of the few therapeutics recommended by the American College of Rheumatology (“ACR”).2 EP-104IAR is an investigational intra-articular (“IA”) treatment that aims to leverage the potent anti-inflammatory activity of an established corticosteroid (fluticasone propionate or “FP”) and combines it with Eupraxia’s patented delivery technology to potentially deliver drug steadily for up to six months. Through a combination of local delivery and carefully modulated drug release, EP-104IAR has the potential to be the first steroid that combines rapid onset and long-duration pain relief with minimal side effects and no impact on cartilage. If successful, EP-104IAR has the capacity to change the treatment paradigm for knee OA – both penetrating and expanding the currently addressable market. EP-104IAR is currently poised to enter Phase 2 development. We have an open IND with the US Food and Drug Administration (“FDA”) and the ability to use the FDA’s 505(b)(2) approval pathway. We are not required to wait for any approvals from the FDA to start the Phase 2 study in the US. Consequently, EP-104IAR offers potentially less regulatory risk than a new chemical entity.

MrMugsy wrote:

lscfa wrote:
Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee. In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

https://www.newswire.ca/news-releases/eupraxia-pharmaceuticals-inc-completes-initial-public-offering-877087844.html

This is an injection - looks like a steroid to me but I can't tell.
Not a concern for our product - IMO.